Evidence map›Paper›PMID 16048984›Full record

Trial reportAntimicrobial agents and chemotherapy2005

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Patrick F Smith, Gregory K Robbins, Robert W Shafer, Hulin Wu, Song Yu, Martin S Hirsch, Thomas C Merigan, Jeong-Gun Park, Alan Forrest, Margaret A Fischl and 2 more

Registry-linked trialAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000919 (Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000919 nacompletednot on this map

Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrolled900ConditionsHIV InfectionsArmsIndinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Patrick F SmithAdult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA. pfsmith@buffalo.edu
Gregory K Robbins
Robert W Shafer
Hulin Wu
Song Yu
Martin S Hirsch
Thomas C Merigan
Jeong-Gun Park
Alan Forrest
Margaret A Fischl
Gene D Morse
ACTG 384-5006 Team

Funding

WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
ZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI ANDERSON, GAIL V · 1985 to 2011
$74.2M
ZIPRASIDONE (GEODON) AUGMENTATION IN SEROTONIN REUPTAKE INHIBITOR-RESISTANT OBM01RR000071 · NCRR · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI NEWCORN, JEFFREY H · 1985 to 2009
$41.5M
Zonisamide in Patients with Neuropathic Pain Associated with Diabetic NeuropathyM01RR000046 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOY, MELANIE S · 1985 to 2008
$38.5M
VEGF VECTOR TO ISCHEMIC MYOCARDIUM W/DIFFUSE CORONARY DISEASEM01RR000047 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI MCQUIGGAN, MARGARET M · 1985 to 2007
$36.4M
ZIPRASIDONE IN NORMAL HEPATIC FUNCTION SUBJECTS &IN HEPATIC DYSFUCTIN SUBJECTSM01RR000037 · NCRR · UNIVERSITY OF WASHINGTON · PI MCDONALD, RUTH C · 1985 to 2007
$33.8M
YOUTH DRUG ABUSE, ADHD, AND RELATED DISRUPTIVE DISORDERSM01RR000400 · NCRR · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BACHANOVA, VERONIKA S · 1985 to 2009
$33.7M
XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH FOOD ALLERGYM01RR000070 · NCRR · STANFORD UNIVERSITY · PI RASGON, NATALIE L · 1985 to 2008
$32.4M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
ZOSUQUIDAR TRIHYDROCHLORIDE DURING CONVENTIONAL INDUCTION AND POST-REMISSIONM01RR000750 · NCRR · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI RODRIGUEZ, HENRY · 1985 to 2008
$25.5M
WOMEN'S HEALTH AGENDAU01AI025868 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ERON, JOSEPH J. · 1987 to 2006
$14.9M
NCRR NIH HHS 1P20RR11126NCRR NIH HHS M01 RR000037NCRR NIH HHS M01 RR000044NCRR NIH HHS M01 RR000046NCRR NIH HHS M01 RR000047NCRR NIH HHS M01 RR000056NCRR NIH HHS M01 RR000070NCRR NIH HHS M01 RR000071NCRR NIH HHS M01-RR-00037NCRR NIH HHS M01 RR000400NCRR NIH HHS M01 RR000425NCRR NIH HHS M01RR00047NCRR NIH HHS M01-RR00056NCRR NIH HHS M01-RR00070NCRR NIH HHS M01-RR-00071NCRR NIH HHS M01 RR000750NCRR NIH HHS M01RR00400NCRR NIH HHS M01-RR00425NCRR NIH HHS M01RR0884NCRR NIH HHS MO1RR00750NCRR NIH HHS P20 RR011126NCRR NIH HHS RR00044NCRR NIH HHS RR00046NIAID NIH HHS 5U01-AI46383NIAID NIH HHS AI25859NIAID NIH HHS AI25868NIAID NIH HHS AI25897NIAID NIH HHS AI27658NIAID NIH HHS AI-27659NIAID NIH HHS AI27659NIAID NIH HHS AI27660NIAID NIH HHS AI27661NIAID NIH HHS AI27664NIAID NIH HHS AI27665NIAID NIH HHS AI27666NIAID NIH HHS AI27670NIAID NIH HHS AI27673NIAID NIH HHS AI34832NIAID NIH HHS AI35162NIAID NIH HHS AI46386NIAID NIH HHS AI50410NIAID NIH HHS P30 AI050410NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI025868NIAID NIH HHS U01 AI025897NIAID NIH HHS U01 AI027658NIAID NIH HHS U01 AI027659NIAID NIH HHS U01 AI027660NIAID NIH HHS U01 AI027661NIAID NIH HHS U01 AI027664NIAID NIH HHS U01 AI027665NIAID NIH HHS U01 AI027666NIAID NIH HHS U01 AI027670NIAID NIH HHS U01 AI027673NIAID NIH HHS U01 AI034832NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI046383NIAID NIH HHS U01 AI046386NIAID NIH HHS U01-AI-27667NIAID NIH HHS UO1-AI38858PHS HHS M01-R00096
6 · The paper itself

Abstract

Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.

Indexed as

AlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesDouble-Blind MethodDrug Therapy, CombinationHIV InfectionsHumansNelfinavirOxazinesReverse Transcriptase InhibitorsTreatment OutcomeAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesefavirenzNelfinavirOxazinesReverse Transcriptase Inhibitors

Identifiers

PMID16048984
PMCPMC1196281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.